Published in Vaccine Weekly, January 31st, 2007
In laboratory studies to date, peramivir has shown effectiveness against a number of influenza strains. Funding provided under the new contract will support further studies to determine if peramivir can be an effective treatment for seasonal and life-threatening influenza, including highly pathogenic H5N1 influenza. Additional research may also examine the drug's potential use for prophylaxis to protect against influenza infection.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly